Newly Diagnosed Acute Myeloid Leukemia (AML) Treatment Considerations

NCCN Guidelines group first-line treatment options into three groups:

  • Patients under 60 years old
  • Patients age 60 years and older who are candidates for intensive chemotherapy (IC)
  • Patients age 60 years and older who are not candidates for IC

Within these groups, treatment is further grouped by disease characteristics of AML, including cytogenetic and mutational status, as well as prior hematologic malignancy history.

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 22, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.